Immediate post-infusion recovery is typically 1–2 weeks; patients usually resume light activity within days. Full immune re-equilibration (as measured by T-cell and antibody profiles) takes 8–12 weeks. Clinical plateau is often reached by month 6. Disease flares can recur at any point, particularly if steroids or immunosuppressants are withdrawn too rapidly; close rheumatology monitoring is essential throughout.
Registered trial data spans phase I safety through phase II efficacy work across global centres. Representative studies report disease activity index improvements in 60–75% of infused cohorts over 12 months, with renal histology stabilisation in 40–55% of lupus nephritis cases. Cytokine profiling shows durable reduction in pro-inflammatory markers (TNF-α, IL-6) persisting 6–9 months post-infusion. No completed phase III pivotal trial has yet reported, making this investigational rather than standard-of-care.
هل أنا مرشح؟ → · Lupus (SLE): full overview → · تكلفة الذئبة الحمراء (SLE) → · Cost →
تم المراجعة الطبية بواسطة فريق التحرير StemCellAtlas مع Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) من عيادة الشريك Stem Plus (صوفيا)، وفقاً لـ ISSCR و FDA و EMA. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية